John Parkinson

The data comes from a phase 1/2 trial with the CoronaVac vaccine.

CDC and WHO Data shows a 50% increase worldwide from 3 years ago.

A study looking at these 2 populations in a hospital setting offers some positive news.

The country halted the Sinovac investigational vaccine due to what was being reported as a serious adverse event.

The federal agency announced Novavax’s, NVX-CoV2373, was granted this designation.

When administered every two months, cabotegravir is 89% more effective than daily pills in preventing HIV acquisition in women.

The company recently announced it was in a phase 1 trial.

The investigational antibody used to treat President Trump shows it reduced viral load and medical visits.

A new study shows disproportionate impact of the virus to this group.

These vital cells that are recovered from COVID-19 patients might be able to help people with compromised immune systems due to cancer therapy or transplantation.

While this trial for hospitalized COVID-19 patients has been discontinued, Lilly is continuing their other trials with the medication for COVID-19 treatment.

The company is planning to move forward after receiving a recommendation from the DSMB to start up the trial again.

A case study examines a treatment for a hospitalized case of the virus.

Investigators wanted to examine spontaneously reported adverse events and whether they were cause for concern.

Here is a look at the patterns within the variety of symptoms and presentations during physician exams.

A presenting author offers greater study insights into this novel therapy for the treatment of serious infections.

Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.

A prospective study looked at the association of contract nursing and SARS-CoV-2 outbreaks.

Investigators wanted to look at real world experiences with combination therapy in older people living with HIV.

Results from the Pivotal ADAPT-PO study were reported.

Results show medication provides therapeutic response for Candida.

In a large nursing home study, asymptomatic and symptomatic residents were found to carry similar viral loads.

A study looked at weight gain when changing therapy regimens.

The participant was taking a placebo and the trial will continue according to initial reports.

Sulopenem was superior to ciprofloxacin for the treatment of uncomplicated urinary tract infections.

In a phase 1/2 randomized clinical trial, GlaxoSmithKline’s RSVPreF3 vaccine elicits a response.

Covaxx has developed its investigational vaccine and is currently in a phase 1/2 trial.

Data from a Phase 1/2 randomized controlled trial of vaccine candidate, BBIBP-CorV, is shown to be safe.

A letter signed by 80 researchers says the concept put forth by the Great Barrington Declaration is “a dangerous fallacy.”

Looking at certain characteristics in a blood test can help forecast patients’ course and inform clinicians’ determination on the course of treatment.